VANDERBILT UNIVERSITY MEDICAL CENTER

Articles from various sources reference studies and reports published in The American Journal of Managed Care, covering topics such as machine learning in healthcare, Medicare Advantage turnover, affordability of GLP-1 drugs, AI-powered robots in respiratory care, updated colonoscopy guidelines, and biosimilar partnerships.

The CBCF ALC panel 'The Road to Health Equity' discussed mistrust in clinical trials among Black communities, citing historical abuses like Tuskegee and Henrietta Lacks. Inclusivity in trials is crucial for medical equity, yet Black Americans are underrepresented. Initiatives like EQBMED aim to increase diversity and trust in clinical research.

USC's Keck School of Medicine launches a $2.7 million NIH-funded, multi-site study to understand how type 1 diabetes affects brain development in children, aiming to refine clinical guidelines and therapeutic approaches.

The article profiles various professionals in health and statistics, including John R. Lumpkin, M.D., M.P.H., Mollyann Brodie, Ph.D., Kennon R. Copeland, Ph.D., Tara Das, Ph.D., M.P.H., M.L.I.S., Scott H. Holan, Ph.D., V. Joseph Hotz, Ph.D., Bradley Malin, Ph.D., Sally C. Morton, Ph.D., Lucila Ohno-Machado, M.D., M.B.A., Ph.D., Andy Peytchev, Ph.D., C. Matthew Snipp, Ph.D., Kelly Hoover Thompson, J.D., and David R. Williams, Ph.D., detailing their roles, achievements, and contributions to their respective fields.

Research by Dag Stormoen reveals similar genetic profiles in early and late-stage urothelial tract cancer, with a small cohort of advanced-stage patients showing long survival. Genetic testing identifies targetable mutations, emphasizing early testing for targeted therapies. The long-surviving cohort is younger and has better performance status, prompting further research on overall health impact on survival.

Vanderbilt University Medical Center joins ReVAMPP, a $100 million/year NIH program to develop vaccines and antibody therapies against viral threats, with a $13 million/year grant for bunyaviruses and picornaviruses research.

NIH establishes pandemic preparedness research network, ReVAMPP, to develop vaccines and monoclonal antibodies for high-priority pathogens, focusing on virus families known to infect humans. NIAID commits $100 million annually to fund the program, aiming to fill knowledge gaps and enhance pandemic response capabilities.

In a Hearing Horizons podcast, Melanie Hamilton-Basich discusses with Angela Bonino, PhD, the challenges children with developmental disabilities face in receiving timely hearing assessments, the need for adapted assessments, and the importance of collaboration with pediatricians for better hearing care.

EQBMED announces Amgen and Merck as sponsors for local clinical trial sites, focusing on oncology and cardiovascular disease, aiming to enhance diversity in clinical trials.

A blood test developed by researchers at UC Davis Health and other institutions may predict the risk of severe respiratory conditions, potentially leading to earlier intervention and prevention of serious lung disease. The test, based on a risk score derived from 32 proteins and 30 years of lung health data, identifies adults likely to develop severe respiratory issues, with higher scores indicating increased risk of hospital care, COPD, and respiratory death. The study, published in the American Journal of Respiratory and Critical Care Medicine, suggests early detection could improve lung function and quality of life.